Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?
Executive Summary
Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call